Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients

Ebid, Abdel-Hameed Ibrahim Mohamed; Ahmed, Ossama Ashraf; Agwa, Sara Hassan; Abdel‐Motaleb, Sara Mohamed; Hagag, Radwa Samir

doi:10.1007/s11096-020-01085-2

Cited by 5 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our results, Ebid et al found no correlation between IL28B genotypes and sustained virologic response to sofosbuvir plus daclatasvir or ombitasvir/paritaprevir/ ritonavir plus ribavirin among Egyptian patients with genotype 4 HCV. Again, in this cohort CT genotype was the predominant one (35) . Moreover, in another study performed on hepatic transplantation hepatitis C Egyptian patients, there was no role for recipient IL28B genotype in the response to DAAs (36) .…”

Section: Figure 2 the Roc Curve Of The Regression Modelmentioning

confidence: 52%

Assessing Predictors of Directly Acting Antivirals’ Failure as a Further Step Towards More Efficient HCV Elimination Programs: Il28b (Ifnl4) Gene Polymorphism Has No Role While Higher Estimated Creatinine Clearance Is a Forgotten Factor

Kamal

Matta

MOHSIN

et al. 2022

Arq. Gastroenterol.

View full text Add to dashboard Cite

Background: Sustained virologic response (SVR) rates after directly acting antivirals (DAAs) for hepatitis C virus (HCV) exceed 95%. This encouraged policymakers to put plans to achieve HCV elimination by 2030. The remaining percentage of non-SVR12 can affect HCV eradication strategies in the real-world especially the compliance of large numbers of treated persons to follow up for assessment of virologic response cannot be guaranteed. Objective: We aimed to assess predictors of failure to achieve SVR after receiving sofosbuvir plus NS5A inhibitor as an important step towards achieving better HCV eradication strategies. Methods: During the period from 1st November 2018 to 1st November 2019, 1581 treatment-naive patients received sofosbuvir plus daclatasvir ± ribavirin at our unit and 10 patients were referred to us with HCV relapse after the same regimens. A total of 163 out of the 1581 patients were lost for follow-up before assessment of virologic response and excluded from the analysis. 20 out of the remaining patients failed to achieve SVR12. Data from the 30 patients with non-SVR12 were included in the case-control analysis. Results: Every unit increase in estimated creatinine clearance using modification of diet in renal disease study (MDRD) score, total bilirubin, and INR was associated with 1.03, 13.92, and 80.08 times greater odds of non-SVR12 (P<0.001, P=0.0016, P=0.02) respectively. The presence of liver cirrhosis on ultrasonography increases the odds by 10.03. (P=0.009). Conclusion: Higher MDRD score, INR, total bilirubin, and presence of sonographic features of liver cirrhosis are predictors of failure to achieve SVR12 using sofosbuvir plus NS5A inhibitor.

show abstract

Section: Figure 2 the Roc Curve Of The Regression Modelmentioning

confidence: 52%

Assessing Predictors of Directly Acting Antivirals’ Failure as a Further Step Towards More Efficient HCV Elimination Programs: Il28b (Ifnl4) Gene Polymorphism Has No Role While Higher Estimated Creatinine Clearance Is a Forgotten Factor

Kamal

Matta

MOHSIN

et al. 2022

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Gene SNPs have been found to be associated with the risk of diseases and the efficacy of drug treatment (Tawfeek and Alhassanin, 2018;Ebid et al, 2020;Pozhidaev et al, 2020;de Assis et al, 2021). The rs2556375 is an eQTL in brain tissue of drug-resistant epilepsy patients.…”

Section: Discussionmentioning

confidence: 99%

A novel BCL11A polymorphism influences gene expression, therapeutic response and epilepsy risk: A multicenter study

Wang

Cai

Liu

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

BackgroundGenetic factors have been found to be associated with the efficacy and adverse reactions of antiseizure medications. BCL11A is an important regulator of the development of neuronal networks. However, the role of BCL11A in epilepsy remains unclear. This study aimed to evaluate the genetic association of BCL11A with the susceptibility to develop epileptic seizures and therapeutic response of patients with epilepsy in Han Chinese.MethodsWe matched 450 epilepsy cases with 550 healthy controls and 131 drug-resistant epilepsy patients with 319 drug-responsive epilepsy patients from two different centers. Genetic association analysis, genetic interaction analysis, expression quantitative trait loci analysis and protein–protein interaction analysis were conducted.ResultsOur results showed that rs2556375 not only increases susceptibility to develop epileptic seizures (OR = 2.700, 95% = 1.366–5.338, p = 0.004 and OR = 2.984, 95% = 1.401–6.356, p = 0.005, respectively), but also increases the risk of drug resistance(OR = 21.336, 95%CI =2.489–183.402, p = 0.005). The interaction between rs2556375 and rs12477097 results in increased risk for pharma coresistant. In addition, rs2556375 regulated BCL11A expression in human brain tissues (p = 0.0096 and p = 0.033, respectively). Furthermore, the protein encoded by BCL11A interacted with targets of approved antiepileptic drugs.ConclusionBCL11A may be a potential therapeutic target for epilepsy. Rs2556375 may increase the risks of epilepsy and drug resistance by regulating BCL11A expression in human brain tissues. Moreover, the interaction between rs2556375 and rs12477097 results in increased risk for drug resistance.

show abstract

“…Interleukin 28B polymorphism as a predictor of sustained virological response to sofosbuvir-based therapy for HCV as a part of sofosbuvir efficacy is more investigated in clinical trials and on HCV genotypes 1, 2, and 3, while its real-life investigation studies particularly in Egypt on HCV genotype 4 is insufficient [10,17,18] As a result pretreatment interleukin 28B genotyping can still be valuable in determining patients who may benefit from shorter treatment courses or deciding the most appropriate treatment decisions when the resources are limited or, in challenging conditions such as the high prevalence as in Egypt with evidence for some continuous HCV transmission [5].…”

Section: Introductionmentioning

confidence: 99%

Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients

Zaki

Ahmed²,

Yousif³

et al. 2022

TropicalMed

View full text Add to dashboard Cite

In various genome-wide correlation studies, interleukin (IL)28B gene polymorphism has been strongly correlated with both the therapeutic and spontaneous mediated clearance of hepatitis C virus (HCV). Therefore, this study aimed to evaluate the genotype and allele frequency distributions of IL28B (rs12979860) in patients with chronic hepatitis C and assess the IL28B polymorphisms as predictors of sustained virological response to SOF-based therapy for HCV in Egyptian patients. This retrospective case-control study was conducted on 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and responded to treatment with SVR12 (the responder group) as a control group, and 54 chronic HCV patients who completed treatment with SOF/DCV ± RBV for 12 weeks and did not respond to treatment and failed to achieve SVR12 (the non-responder group) as a case group. The CC genotype frequency of IL-28B (rs12979860) was greater in the responder group (51.9%). In contrast, the TT genotype frequency was higher in the non-responder group (48.1%) (p < 0.001), and the T allele significantly increased the risk of non-responses by 3.13 fold. Therefore IL-28B (rs12979860) SNP could be used as a genetic predictor of sustained virological response to SOF+DCV ± RBV-based HCV treatment in Egyptian patients.

show abstract

Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients

Cited by 5 publications

References 33 publications

Assessing Predictors of Directly Acting Antivirals’ Failure as a Further Step Towards More Efficient HCV Elimination Programs: Il28b (Ifnl4) Gene Polymorphism Has No Role While Higher Estimated Creatinine Clearance Is a Forgotten Factor

Assessing Predictors of Directly Acting Antivirals’ Failure as a Further Step Towards More Efficient HCV Elimination Programs: Il28b (Ifnl4) Gene Polymorphism Has No Role While Higher Estimated Creatinine Clearance Is a Forgotten Factor

A novel BCL11A polymorphism influences gene expression, therapeutic response and epilepsy risk: A multicenter study

Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients

Contact Info

Product

Resources

About